Diabetes Treatment and Research at Yale Medicine School: 30 Years of Progress
July 20, 2022
July 20, 2022
NEW HAVEN, Connecticut, July 20 (TNSjou) -- Yale School of Medicine issued the following news:
The New England Journal of Medicine reported an important finding in 2019 from a Yale-led clinical trial: for the first time, researchers showed that a drug, teplizumab, could delay the development of type 1 diabetes by two years.
Kevan Herold, MD, C.N.H. Long Professor of Immunology and professor of medicine (endocrinology), and the principal investigator of the trial, said t . . .
The New England Journal of Medicine reported an important finding in 2019 from a Yale-led clinical trial: for the first time, researchers showed that a drug, teplizumab, could delay the development of type 1 diabetes by two years.
Kevan Herold, MD, C.N.H. Long Professor of Immunology and professor of medicine (endocrinology), and the principal investigator of the trial, said t . . .